Clinical Trials Logo

ER Positive Breast Cancer clinical trials

View clinical trials related to ER Positive Breast Cancer.

Filter by:
  • Withdrawn  
  • Page 1

NCT ID: NCT04901299 Withdrawn - Clinical trials for Metastatic Breast Cancer

Fulvestrant + Neratinib In Breast Cancer

HER2-Signal
Start date: July 2023
Phase: Phase 2
Study type: Interventional

This is a Phase 2 open label, multi-center non-randomized interventional study designed to evaluate the safety and efficacy of combining Neratinib plus Fulvestrant in previously treated metastatic HR-positive, HER2-negative breast cancer. - This research study involves the study drug Neratinib - The standard of care drug Fulvestrant

NCT ID: NCT01361945 Withdrawn - Breast Cancer Clinical Trials

AUY922 With Lapatinib and Letrozole for ER+ HER2+ Advanced Breast Cancer

Start date: July 2011
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to find out what effects, administering infusions of AUY922 with hormonal therapy (letrozole) and oral targeted drug (lapatinib) will have on the patients with advanced breast cancer known as ER+ HER2 +.